Research ArticleOriginal Article
Open Access

Hormone receptor status and survival of medullary breast cancer patients

A Turkish cohort

Asude Aksoy, Hatice Odabas, Serap Kaya, Oktay Bozkurt, Mustafa Degirmenci, Turkan O. Topcu, Aydın Aytekin, Erkan Arpaci, Nilufer Avci, Kezban N. Pilanci, Havva Y. Cinkir, Yakup Bozkaya, Yalcin Cirak and Mahmut Gumus
Saudi Medical Journal February 2017, 38 (2) 156-162; DOI: https://doi.org/10.15537/smj.2017.2.18055

References

  1. ↵
    1. Martinez SR,
    2. Beal SH,
    3. Canter RJ,
    4. Chen SL,
    5. Khatri VP,
    6. Bold RJ
    (2011) Medullary carcinoma of the breast: a population-based perspective. Med Oncol 28:738–744.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Mateo AM,
    2. Pezzi TA,
    3. Sundermeyer M,
    4. Kelley CA,
    5. Klimberg VS,
    6. Pezzi CM
    (2016) Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base. J Surg Oncol 114:533–536.
    OpenUrl
    1. Bayraktar S,
    2. Amendola L,
    3. Gutierrez-Barrera AM,
    4. Hashmi SS,
    5. Amos C,
    6. Gambello M,
    7. et al.
    (2014) Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 23:770–774.
    OpenUrl
  4. ↵
    1. Petekkaya I,
    2. Babacan T,
    3. Sarici F,
    4. Gezgen G,
    5. Roach EC,
    6. Kizilarslanoglu MC,
    7. et al.
    (2013) Medullary carcinoma of the breast: a brief report from a tertiary care center. J BUON 18:798.
    OpenUrl
  5. ↵
    1. Dai X,
    2. Li Y,
    3. Bai Z,
    4. Tang XQ
    (2015) Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers. Sci Rep 5:14499.
    OpenUrl
  6. ↵
    1. Hammond ME
    (2011) ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol 19:499–500.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Gourgou-Bourgade S,
    2. Cameron D,
    3. Poortmans P,
    4. Asselain B,
    5. Azria D,
    6. Cardoso F,
    7. et al.
    (2015) Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative; Definition for the Assessment of Time-to-event Endpoints in CancerTrials Initiative. Ann Oncol 26:873–879.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lim S,
    2. Park SH,
    3. Park HK,
    4. Hur MH,
    5. Oh SJ,
    6. Suh YJ
    (2015) Prognostic role of adjuvant chemotherapy in node-negative (N0), triple-negative (TN), medullary breast cancer (MBC) in the Korean population. PLoS One 10:e0140208.
    OpenUrl
  9. ↵
    1. Park I,
    2. Kim J,
    3. Kim M,
    4. Bae SY,
    5. Lee SK,
    6. Kil WH,
    7. et al.
    (2013) Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma. J Breast Cancer 16:417–425.
    OpenUrlCrossRefPubMed
    1. Wang XX,
    2. Jiang YZ,
    3. Liu XY,
    4. Li JJ,
    5. Song CG,
    6. Shao ZM
    (2016) Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget 19(7):22665–22673.
    OpenUrl
  11. ↵
    1. Jiménez-Villanueva X,
    2. Hernández-Rubio A,
    3. García-Rodríguez FM,
    4. García RG,
    5. Moreno-Eutimio M,
    6. Herrera-Torre A
    (2014) Medullary carcinoma experience in breast oncology unit of Hospital Juarez Mexico. Cir Cir 82:20–27.
    OpenUrl
  12. ↵
    1. Montagna E,
    2. Maisonneuve P,
    3. Rotmensz N,
    4. Cancello G,
    5. Iorfida M,
    6. Balduzzi A,
    7. et al.
    (2013) Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 13:31–39.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Woodson AH,
    2. Profato JL,
    3. Muse KI,
    4. Litton JK
    (2013) Breast cancer in the young: role of the geneticist. J Thorac Dis 51:19–26.
    OpenUrl
  14. ↵
    1. Liukkonen S,
    2. Leidenius M,
    3. Saarto T,
    4. Sjöström-Mattson J
    (2011) Breast cancer in very young women. Eur J Surg Oncol 37:1030–1037.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Chu Z,
    2. Lin H,
    3. Liang X,
    4. Huang R,
    5. Zhan Q,
    6. Jiang J,
    7. et al.
    (2014) Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases. PLoS One 9:e111493.
    OpenUrl
  16. ↵
    1. Romaniuk A,
    2. Lyndin M,
    3. Sikora V,
    4. Lyndina Y,
    5. Panasovska K
    (2015) Histological and immunohistochemical features of medullary breast cancer. Folia Med Cracov 55:41–48.
    OpenUrl
  17. ↵
    1. Ridolfi RL,
    2. Rosen PP,
    3. Port A,
    4. Kinne D,
    5. Miké V
    (1977) Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 40:1365–1385.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Huober J,
    2. Gelber S,
    3. Goldhirsch A,
    4. Coates AS,
    5. Viale G,
    6. Öhlschlegel C,
    7. et al.
    (2012) Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 23:2843–2851.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hashmi AA,
    2. Edhi MM,
    3. Naqvi H,
    4. Faridi N,
    5. Khurshid A,
    6. Khan M
    (2014) Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol 28:43.
    OpenUrl
  20. ↵
    1. Shokouh TZ,
    2. Ezatollah A,
    3. Barand P
    (2015) Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes retrospective-observational analytical study. Medicine (Baltimore) 94:e1359.
    OpenUrl
  21. ↵
    1. Cao AY,
    2. He M,
    3. Huang L,
    4. Shao ZM,
    5. Di GH
    (2013) Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified. World J Surg Oncol 11:91.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Rakha EA,
    2. El-Sayed ME,
    3. Green AR,
    4. Paish EC,
    5. Powe DG,
    6. Gee J,
    7. et al.
    (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772–4778.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Chen S,
    2. Huang L,
    3. Chen CM,
    4. Shao ZM
    (2015) Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. Oncotarget 6:18174–18182.
    OpenUrl
  24. ↵
    1. Rakha EA,
    2. Aleskandarany M,
    3. El-Sayed ME,
    4. Blamey RW,
    5. Elston CW,
    6. Ellis IO,
    7. et al.
    (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45:1780–1787.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Sinn HP,
    2. Kreipe H
    (2013) A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care (Basel) 8:149–154.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Miller CV,
    2. Cook IS,
    3. Jayaramachandran R,
    4. Tyers AG
    (2014) Spontaneous regression of a conjunctival malignant melanoma. Orbit 33:139–141.
    OpenUrl
  27. ↵
    1. Igawa T,
    2. Sato Y,
    3. Kawai H,
    4. Kondo E,
    5. Takeuchi M,
    6. Miyata-Takata T,
    7. et al.
    (2015) Spontaneous regression of plasmablastic lymphoma in an elderly human immunodeficiency virus (HIV)-negative patient. Diagn Pathol 10:183.
    OpenUrl
  28. ↵
    1. Van Verschuer VM,
    2. Hooning MJ,
    3. van Baare-Georgieva RD,
    4. Hollestelle A,
    5. Timmermans AM,
    6. Koppert LB,
    7. et al.
    (2015) Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer. Hum Pathol 46:182–190.
    OpenUrl
    1. Li X,
    2. Zhang G,
    3. Chen Q,
    4. Lin Y,
    5. Li J,
    6. Ruan Q,
    7. et al.
    (2016) CD317 Promotes the survival of cancer cells through apoptosis-inducing factor. J Exp Clin Cancer Res 35:117.
    OpenUrl
  30. ↵
    1. Walsh MF,
    2. Nathanson KL,
    3. Couch FJ,
    4. Offit K
    (2016) Genomic biomarkers for breast cancer risk. Adv Exp Med Biol 882:1–32.
    OpenUrl
  31. ↵
    1. Mavaddat N,
    2. Pharoah PD,
    3. Michailidou K,
    4. Tyrer J,
    5. Brook MN,
    6. Bolla MK,
    7. et al.
    (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107:pii–djv036.
    OpenUrl
  32. ↵
    1. Rashid MU,
    2. Muhammad N,
    3. Bajwa S,
    4. Faisal S,
    5. Tahseen M,
    6. Bermejo JL,
    7. et al.
    (2016) High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer 16:673.
    OpenUrlCrossRef
  33. ↵
    1. Pedersen L,
    2. Zedeler K,
    3. Holck S,
    4. Schiødt T,
    5. Mouridsen HT
    (1991) Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Based on prognostic observations and observations on inter- and intraobserver variability of 11 histopathological characteristics in 131 breast carcinomas with medullary features. Br J Cancer 63:591–595.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section